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ABSTRACT  
In chronic kidney disease (CKD), tubular cells are thought to be involved in the induction of 
interstitial fibrosis, which in turn leads to loss of renal function. The molecular mechanisms 
that link tubular cells to the interstitial compartment are not clear. Here, we combined an 
experimental model of nephron reduction, mice from different genetic backgrounds and 
genetically modified animals with in silico and in vitro experiments, to demonstrate that the 
selective activation of Stat3 in tubular cells is crucial for the development of interstitial 
fibrosis. Stat3 was activated exclusively in tubular cells of lesion-prone mice after nephron 
reduction. The specific inactivation of Stat3 in tubular cells resulted in reduced fibroblast 
proliferation and matrix synthesis. As a consequence, the extent of interstitial fibrosis was 
significantly reduced in Stat3Δtub transgenic mice. Mechanistically, tubular Stat3 activation 
triggered the expression of a specific subset of paracrine profibrotic factors, including Lcn2, 
Pdgfb and Timp1. Together, our results provide a molecular link between tubular and 
interstitial cells during CKD progression and identify Stat3 as a central regulator and a 
promising therapeutic target.  
 
 
Key words: Stat3/kidney/fibrosis/paracrine mediators/Lcn2 
 
 3 
INTRODUCTION 
Chronic reduction of renal function, the common denominator of chronic kidney diseases 
(CKD), represents a worldwide health concern. Grossly, 10% of the adult population is 
estimated to suffer from CKD1. These patients display an increased risk of death and 
cardiovascular morbidity that is proportional to the decline of renal function2, 3. Moreover, due 
to its progressive nature, CKD may lead to end-stage renal disease (ESRD), which requires 
renal replacement therapy substantially altering life quality and expectancy.  
Regardless of the initial insult, all CKD are thought to share a common mechanism of 
progression by which the overwork imposed by compensation to the remaining nephrons 
leads to further nephron loss4 which leads to the development of renal lesions. The identity of 
the molecular networks at the origin of the initial compensatory processes and the 
mechanisms leading to the subsequent appearance of lesions has only been partially 
elucidated. Clinical studies have shown that the decline of renal function correlates more 
closely with the severity of interstitial fibrosis than with glomerular damage5-7. Recent finding 
indicate that the activation of renal fibroblasts by paracrine factors play a critical role in the 
development of renal fibrosis8. It is known that the overwork imposed by adaptation lead to 
mechanical and metabolic stresses of tubular cells, which in turn start to synthesize soluble 
mediators of CKD progression, i.e. cytokines and profibrotic growth factors. Similarly, 
leakage of albumin from the damaged glomerular barrier also leads to the damage of tubular 
cells with the subsequent production of profibrotic mediators. Thus, it is tempting to speculate 
that, by delivering fibrogenic paracrine cues to interstitial fibroblasts, tubular cell activation is 
a crucial step of CKD progression.  
Signal transducers and activators of transcription (Stats) are versatile transcription factors that 
mediate the intra-cellular signaling of various molecular pathways9. Stat activation begins by 
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their recruitment to membrane receptors where they are phosphorylated, either directly by 
receptors with tyrosine kinase activity or indirectly by receptor-associated tyrosine kinases. 
This phosphorylation allows both dimerization and nuclear accumulation of the activated Stat, 
which binds to cognate elements on promoters of responsive genes10. Among the 7 known 
Stat genes, Stat3 displays unique features. It has the largest spectrum of potential activators 
including various cytokines, hormones and growth factors11. Contrary to the other members, 
Stat3 is the only one whose inactivation leads to embryonic lethality in mice12. Another 
peculiar characteristic of Stat3 is its ability to regulate gene networks that are highly variable 
from one cell type to another one13-17. In addition, Stat3 has been described to have non-
transcriptional roles in regulating cell migration18 and mitochondrial electron transport chain19, 
20.  
Recent studies have implicated Stat3 in the progression of CKD. Indeed, in several human 
and experimental nephropathies, Stat3 activation has been shown in different compartments 
of the damaged kidney, including tubular cells21-28. Interestingly, both Stat3 haploinsufficiency 
and Stat3 pharmacological inhibition have been shown to decrease lesion progression in HIV-
associated nephropathy26, experimental diabetes24 or ureteral obstruction29. Although these 
studies were conducted in specific experimental models, they point to Stat3 as an important 
mediator of CKD progression. However, the molecular mechanisms involved in the 
deleterious effect of Stat3 remain to be elucidated. Remarkably, a few studies have 
demonstrated that Stat3 is mechanistically involved in the communication between epithelial 
cells and fibroblasts30-32. Taking all these data together, we hypothesized that Stat3 
orchestrates the communication between tubular and interstitial cells, leading to the 
development of interstitial fibrosis.  
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RESULTS 
Tubular Stat3 activation precedes renal lesion development after nephron reduction 
To investigate whether the activation of Stat3 is a common feature of CKD progression, we 
analyzed Stat3 (Y706) phosphorylation after subtotal nephrectomy (Nx) in three mouse strains 
that differently react to Nx33, 34. We chose this model, since nephron reduction characterizes 
the evolution of most human CKD. Consequently, this model recapitulates many features of 
human CKD, including hypertension, proteinuria, glomerular and tubulo-interstitial lesions. 
Immunohistochemistry revealed p-Stat3 (Y706) positive cells in the tubules and interstitium of 
the damaged kidneys of the lesion-prone FVB/N mice, but not in the remnant kidneys of the 
resistant C57BL/6 and B6D2F1 mice (Figure 1A). A time course analysis showed that the 
activation of Stat3 in tubular cells preceded the development of renal lesions 42 days after Nx 
(Figure 1, B and C). Sixty days after Nx, when frank renal lesions developed in FVB/N 
mice, Stat3 phosphorylation was still observed in renal tubules as well as in interstitial cells. 
In contrast, glomerular staining was rarely observed (data not shown). Analysis of serial 
sections stained for p-Stat3 (Y706) and specific tubular markers revealed that Stat3 activation 
localized principally to the ascending loop of Henle and collecting duct at day 42 (Figure 2). 
Notably, 60 days after Nx, Stat3 phosphorylation was also observed in damaged proximal 
tubules (Figure 2).  
Tubular specific Stat3 deletion reduces tubulo-interstitial lesions after nephron 
reduction  
We then assessed the functional consequence of tubular Stat3 activation during CKD 
progression. Towards this aim, we first introduced the Stat3flox and Ksp.creERT2 alleles in the 
lesion-prone (FVB/N) genetic background35, 36. Then, we deleted Stat3 specifically in tubular 
cells (Stat3Δtub mice) by crossing Stat3 floxed adult mice (Stat3flox) with the Ksp.creERT2 deleter 
strain, which drives a tamoxifen dependent recombination of the floxed alleles in renal tubular 
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cells35. Indeed, by crossing these mice with a reporter Rosa26.lacZ strain, we confirmed that 
the expression of LacZ activity was exclusively located to renal tubules with a less efficient 
targeting of its proximal parts (Supplemental Figure 1). PCR experiments on different 
organs confirmed the kidney specific Stat3flox allele recombination (Stat3Δtub mice) (Figure 
3A). Two weeks after tamoxifen treatment, the amount of Stat3 protein was reduced by more 
than 50% in kidneys of Stat3Δtub mice as compared to Stat3flox littermates (Figure 3B). Stat3 
immunostaining confirmed the marked decrease of Stat3 expression in renal tubular cells 
(Figure 3C).  
We next applied our experimental model of Nx to both Stat3flox and Stat3Δtub mice, two weeks 
after tamoxifen treatment. Notably, the selective inactivation of Stat3 in tubular cells was 
sufficient to prevent Stat3 (Y706) phosphorylation in whole kidney 60 days after Nx, indicating 
that the bulk of Stat3 activation occurs in tubular cells (Figure 3D). Consistently, the 
expression of Socs3 mRNA, a well–characterized target of Stat3, was significantly decreased 
in Stat3Δtub mice as compared to Stat3flox littermates (Figure 3E). As expected, tubular Stat3 
invalidation had a significant impact on the development of tubular lesions after Nx. Indeed, 
the extent of tubular dilations was reduced by 35% in Stat3Δtub mice as compared to Stat3flox 
littermates (Figure 4). More strikingly, preventing Stat3 activation in tubular cells had a 
marked impact on interstitial fibrosis, which was three fold less severe in Stat3Δtub mice as 
compared to Stat3flox littermates (Figure 4). In contrast, glomerular lesions were mild and did 
not differ between the two mouse genotypes. Together these results indicate that Stat3 
activation in tubular cells promotes interstitial fibrosis after Nx.  
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Tubular Stat3 does not affect tubular cell turnover or functional differentiation 
Tubular dilation is frequently the consequence of increased cell proliferation or impaired 
apoptosis37, 38. To get further insights into the mechanisms by which Stat3 promotes tubular 
dilations, we assessed tubular proliferation and apoptosis in mutant and control mice 90 days 
after Nx by using PCNA staining and TUNEL assay. Surprisingly, Stat3 tubular invalidation 
prevented tubular dilation without impacting tubular cell proliferation or increasing cell 
apoptosis (Supplemental Figure 2, A and B). 
In parallel, in order to determine if Stat3 invalidation might impact tubular functions, we 
measured the relative expression of important transcript for proximal tubule (Megalin, Pepck, 
Slc34a1 and Slc34a3), thick ascending limb (Slc12a1 and Umod), distal tubule (Slc12a3 and 
Calb1) and collecting duct (Scnn1, Aquaporin 2 and Slc4a1) functions. Among these genes, 
only the expression of Megalin, Scnn1 (which codes the α subunit of the epithelial sodium 
channel) and Slc4a1 (which codes anion exchanger 1) were reduced after Nx. More 
importantly, tubular Stat3 deletion did not impact the expression of any of these genes 
(Supplemental Figure 3).  
Tubular Stat3 activation promotes interstitial matrix and fibroblast accumulation 
We then sought to elucidate the mechanisms by which the activation of Stat3 in tubular cells 
influences the accumulation of matrix in the interstitium. In this aim, we first quantified the 
expression of the main collagen proteins known to accumulate during the fibrogenetic process 
and found that collagen I (Col1a1), III (Col3a1) and IV (Col4a1) alpha-1 chain mRNA 
expression was markedly reduced in that Stat3Δtub mice as compared to Stat3flox mice after Nx 
(Figure 5A). Alpha-smooth muscle actin-positive (α−sma+) interstitial fibroblasts are 
considered the main producers of collagen in damaged kidneys39. Interestingly, we observed 
that the number of α−sma+ cells was dramatically decreased in remnant kidneys of Stat3Δtub 
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mice as compared to Stat3flox littermates (Figure 5B). In contrast, Stat3 deletion did not 
prevent the increase of another distinct fibrogenic interstitial cell population, the S100a4+ 
cells40 (Figure 5C). Recent fate tracing experiments performed in other experimental CKD 
models indicate that epithelial to mesenchymal transition does not significantly contribute to 
the expansion of the interstitial myofibroblastic population, which instead derives form renal 
pericytes and/or resident fibroblasts41-43. In line with these observations, we observed that α-
sma+ cells frequently co-stained with the pericyte marker platelet-derived growth factor 
receptor  β (Pdgfr-β) (Figure 5D). Of note, renal tubular cells remained constantly negative 
for α−sma staining after Nx. More importantly, localization analysis of α-sma, Pdgfr-β and p-
Stat3 (Y706) on serial sections revealed clusters of α−sma+/Pdgfr-β+  cells organized along 
tubules with p-Stat3+ nuclei (Figure 5D). As previously shown after unilateral ureteral 
obstruction22, α−sma+/Pdgfr-β+  cells were also positive for p-Stat3 (Y706). Collectively, these 
results suggest that, during CKD, tubular Stat3 stimulates the activation of interstitial 
fibroblasts, likely via the secretion of (a) paracrine factor(s). 
Identification of the potential Stat3 target genes involved in the tubulo-interstitial 
paracrine signal 
To identify the potential direct target genes of Stat3 that may mediate fibroblast activation, we 
took advantage of a method that we recently developed to predict Stat3 functional binding 
sites through comparative genomics16. Using this approach, we re-analyzed the results of a 
transcriptome profiling that we previously carried out in remnant kidneys from the lesion-
prone FVB/N and lesion-resistant C57BL/6 mice. We identified 1815 transcripts whose 
expression significantly differed between FVB/N and C57BL/6 mice 60 days after Nx. 
Among them, 1069 were up-regulated in FVB/N remnant kidneys, whereas 746 were down-
regulated. Interestingly, we observed an enrichment of Stat3 conserved binding sites (CBS) in 
the genes differentially expressed between the lesion-prone and the lesion-resistant mice 
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(Figure 6A). Consistent with the fact that Stat3 behaves mainly as a transcriptional 
activator14, Stat3 CBS enrichment concerned preferentially the up-regulated genes. We next 
decided to focus our analysis on the 570 genes with a Stat3 CBS conserved in at least 4 
species (Figure 6B and Supplemental Table 1). To refine our analysis we systematically 
retrieved Entrez Gene Database, UniprotKB database and MGI Phenotypes and Mutants 
Community Resources for the 570 genes and assessed their potential role in fibroblasts 
activation. Among them, we identified 16 genes encoding for paracrine molecules that could 
account for the tubulo-interstitial communication (Table 1).  
Tubular specific Stat3 inactivation reduces the expression of distinct genes promoting 
extracellular matrix accumulation after nephron reduction 
Quantitative RT-PCR confirmed that six of the potential candidates were significantly altered 
in remnant kidneys of FVB/N mice 60 days after after Nx (Figure 7). Among these genes, 
only three showed Stat3 dependent up-regulation after Nx: Lcn2, Pdgfb and Timp1 (Figure 
7). Colocalization studies revealed that Lcn2, Timp-1 protein as well as Pdgfb mRNA 
localized to p-Stat3 (Y706) positive tubular cells 60 days after Nx (Figure 8, A, B and C), 
supporting the hypothesis of a cell autonomous regulation by Stat3. The colocalization was 
however not found in all the tubular cells, indicating Stat3 independent expression of these 
genes and/or tubular reabsorption of secreted proteins. We then switched to an in vitro 
approach to test whether Lcn2, Timp-1 and Pdgfb are direct targets of Stat3 in renal tubular 
cells. In this aim, we treated mIMCD3 cells with three Stat3 activators of the interleukin 6 
family: Oncostatin M (Osm), Leukemia inhibiting factor (Lif) and Interleukin-6 (IL-6). We 
used these three well-characterized activators of Stat3 because we found that their expression 
was specifically increased in remnant kidneys of FVB/N mice 60 days after surgery as 
compare to sham-operated mice (Supplemental Figure 4). Of these three cytokines, Osm 
induced the strongest phosphorylation of Stat3 in vitro (Figure 8D), which correlated with the 
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strongest induction of Socs3 mRNA expression (Figure 8E). Notably, Osm treatment resulted 
in a significant increase of Lcn2, Timp-1 and Pdgfb mRNA (Figure 8E). To unequivocally 
determine if this activation was dependent by Stat3, we used lentiviral transduction of short 
hairpin RNA to knock-down Stat3 expression (Figure 8F). In line with our hypothesis, we 
observed that Stat3 knock-down blunted the up-regulation of Lcn2, Timp-1 and Pdgfb 
transcript in response to Osm (Figure 8G).  
Lcn2 promotes collagen expression in tubular cells. 
Both Pdgfb and Timp-1 have been shown to induce fibroblasts proliferation44-46. In contrast, 
evidence regarding the fibrogenic potential of Lcn2 are scarce. Recently, Lcn2 was shown to 
enhance Col1 mRNA expression in fibroblasts47. To assess if Lcn2 could modulate collagen 
production in renal tubular cells (mIMCD-3), we used lentiviral transduction of short hairpin 
RNA to knock-down Lcn2 expression (Figure 9A). mIMCD-3 cells expressed both Col1a1 
and Col4a1, but not Col3a1 (data not shown). Tubular Lcn2 knock-down was associated with 
a reduction of both Col1a1 and Col4a1 mRNA expression (Figure 9B). Interestingly, these 
finding were relevant in vivo. In fact, we observed, in damaged kidneys of Nx mice, an 
increase of Col4a1 deposition in the vicinity of tubules expressing Lcn2 (Figure 9C). In 
addition, Col4a1 signal was preferentialy detected in the cytoplasm of Lcn2-positive cells. 
Together these results suggest that Lcn2 acts as a fibrogenic factor by promoting collegen 
synthesis by tubular cells. 
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DISCUSSION 
The accumulation of extracellular matrix in the renal interstitium plays a central role in CKD 
progression. Recent fate tracing experiments have identified activated α-sma+ interstitial 
fibroblast as the principal cell type responsible for matrix deposition into the interstitium39, 43. 
However, tubular cells are the primary target of critical factors implicated in CKD 
progression such as proteinuria, toxic injuries or mechanical stresses. The mechanisms 
translating tubular cell injuries to interstitial fibroblast activation remain unclear. By applying 
an experimental model of nephron reduction to mice carrying a specific deletion of Stat3 in 
tubular cells, we have disclosed a novel paracrine network that is crucially involved in the 
communication between the damaged tubular cells and the surrounding fibroblasts during 
CKD progression. Mechanistically, tubular Stat3 activation triggered the activation of 
interstitial fibroblasts/pericytes, which ultimately lead to the development of interstitial 
fibrosis. Furthermore, we have discovered that Stat3 acts through the induction of a peculiar 
subset of profibrotic genes, i.e. Lcn2, Pdgfb and Timp1. Collectively, this work provides the 
first experimental evidence for a role of tubular cells in the development of renal fibrosis and 
identify in Stat3 a critical regulator.  
Although several studies have demonstrated an activation of Stat3 in tubular cells in both 
human and experimental nephropathies22-28, the functional consequences of such activation are 
still unknown. Our study points to tubular Stat3 activation as the first of a cascade of events 
leading the proliferation of the neighbouring fibroblasts and the subsequent development of 
interstitial fibrosis.  After almost two decades of controversy, fate tracing experiments have 
firmly established that the majority of α-sma+ cells does not derive from tubular cells through 
epithelial-mesenchymal transition but rather from resident interstitial cells corresponding to 
renal fibroblasts and/or pericytes41-43. At the same time, several studies have clearly 
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demonstrated that activation of tubular cells parallels the development of interstitial fibrosis48-
50, suggesting that the interaction between these two compartments might play a crucial role in 
CKD progression. By showing that the selective inactivation of Stat3 in tubular cell prevented 
the development of interstitial fibrosis, our study provides direct evidence in favor of this 
idea. More importantly, we have deciphered a novel paracrine network between tubular and 
interstitial cells governed by Stat3 activation in the former cells. In this context, we have 
identified three potential soluble profibrotic effectors of tubular Stat3 activation: Lcn2, Pdgfb 
and Timp1. Several evidence support the idea that these molecules may be the critical triggers 
of the fibrogenetic process in this specific network. First, interstitial fibroblasts/pericytes 
constitutively express the β isoform of the Pdgf receptor and exogenous Pdgfb administration 
result in fibroblast activation and renal fibrosis51. In addition, pharmacologic inhibition of 
Pdgfb signaling reduces renal fibrosis in experimental CKD52. Second, we previously showed 
that the expression of Lcn2 (also named NGAL), a secreted molecule, which binds 
siderophore53 is up-regulated in both human and rodent CKD54. Lcn2 has been shown to 
interact with the matrix metallopeptidase 9 (Mmp9)55, a peptidase involved in kidney matrix 
turnover. Interestingly, Lcn2 gene inactivation reduces the development of interstitial fibrosis 
after Nx54. Our results showing that Lcn2 increases collagen production in renal tubular cells 
provide further evidence for a direct link between Lcn2 and renal fibrosis. Finally, although 
genetic manipulations of Timp1 have led to contradictory results in experimental CKD56, 57, it 
is likely that the marked reduction of Timp1 might partially contribute to the beneficial effect 
of Stat3 deletion in Nx mice. In fact, it is acknowledged that the balance between matrix 
metalloproteases and matrix metalloprotease inhibitors synthesis determines the extent of 
matrix accumulation58. Beyond its direct impact on matrix degradation, Timp1 has been 
shown to promote fibroblast proliferation providing another potential pathophysiologic 
fibrogenic function for this molecule45, 46. 
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An important corollary finding of this study is that tubular Stat3 induced the accumulation of 
interstitial matrix through the induction of a specific and original subset of profibrotic genes. 
Strikingly, Stat3 deletion impacted neither the expression of Tgf-β2 nor that of CTGF, a well-
characterized profibrotic transcriptional target of canonical Tgf-β signaling, suggesting that 
Stat3 signals orthogonally to Tgf-β in this context59. Of note, the expression of several other 
profibrotic genes including endothelin 1 or fibronectin, that we showed increased after Nx, 
were also unaffected by Stat3 deletion. Hence, it seems that the progression of renal fibrosis is 
fuelled by the intricacy of distinct transcriptional programs that can be independently targeted 
to reduce the extent of renal damage. Tgf-β signaling is to date the most studied contributor to 
the renal fibrosis and therapeutic strategies aiming at its inhibition have evolved to phase I 
and phase II clinical studies60. However, in other pathologic contexts, Tgf-β inhibition has 
recently been shown to be insufficiently effective and associated with significant side 
effects61. Our finding points at Stat3 inhibition as an alternative and/or a synergic therapeutic 
approach to Tgf-β inhibition in CKD.  
A striking observation of this study is that the beneficial effect of Stat3 deletion on tubular 
dilations was associated neither with a decrease of cell proliferation, nor with an increase of 
apoptosis. These results suggest that tubular Stat3 triggers tubular dilations through a 
mechanisms that is independent from proliferation or apoptosis and might involve planar cell 
polarity (PCP). In fact, it has been reported that a defect in the orientation of the mitotic 
spindle (oriented cell divsion) participates to tubular dilation62. Interestingly, during zebrafish 
gastrulation, Stat3 has been shown to control PCP signalling63.    
An unresolved question is the nature of the event(s) leading to Stat3 activation in tubular cells 
after nephron reduction. Important factors for CKD progression such as albuminuria and 
Epidermal Growth Factor Receptor (EGFR) activate Stat3 in cultured epithelial cells64. 
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However, it is unlikely that these factors induce Stat3 activation in a cell autonomous manner 
in our model. Indeed, both albuminuria mediated tubular damage and EGFR activation occurs 
mainly in the proximal tubules whereas we detected Stat3 activation mainly in the distal part 
of the nephron65, 66. Moreover, the deleter Ksp.creERT2 strain we used to inactivate Stat3flox 
allele in tubular cells principally targets the ascending loop of Henle and the collecting duct. 
Thus, the reduction of the interstitial fibrosis observed in this model likely reflects Stat3 
function in the distal rather than in the proximal part of the nephron. In this context, the bona 
fide activator(s) of Stat3 in this segment remain to be identified. Interestingly, we observed 
that Oncostatin mRNA was up-regulated after Nx and that this cytokine stimulated the 
expression of Pdgfb, Timp-1 and Lcn2 in a Stat3 dependent manner in cultured renal 
epithelial cells. Whether or not Oncostatin plays the same role in vivo remains to be assessed.  
In conclusion, this work established the critical role played by tubular cells in the 
development of interstitial fibrosis after nephron reduction.  We have also identified Stat3 as a 
master gene of the paracrine molecular network linking tubular and interstitial compartment 
during CKD progression. Other studies have previously showed the deleterious impact of 
Stat3 activation in glomeruli24, 26, 67, 68. Therefore, Stat3 seems to be a promising therapeutic 
target for the maintenance of both the glomerular and tubulo-interstitial compartment during 
chronic kidney disease. 
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METHODS 
Animals 
Mice used for these studies were female FVB/N, C57BL/6 and C57BL/6xDBA2/F1 
(B6D2F1) (Charles River), Ksp.creERT2 mice35, 36, Stat3flox mice35, 36, and Rosa26LacZ mice 
(Jackson Laboratories). FVB/N Stat3flox and Ksp.creERT2 were obtained by backcrossing 
heterozygous C57BL/6 Stat3flox/+ and Ksp.creERT2 mice on an FVB/N background for at least 
five generations before the first intercross. Animals were fed ad libitum and housed at 
constant ambient temperature in a 12-hour light cycle. Animal procedures were approved by 
the Departmental Director of “Services Vétérinaires de la Préfecture de Police de Paris” and 
by the ethical committee of the Paris Descartes University. 
Protocol 
All experiments were performed on 9-week-old female mice. Protocols involving transgenic 
mice were performed on littermate mice. Mice were subjected to 75% nephrectomy (Nx) or 
sham operation (Sh), as previously described33. After surgery, mice were fed a defined diet 
containing 30% casein and 0.5% sodium. Several groups of mice were investigated in 
complementary studies. For Stat3 activation time course experiments, 6 mice were studied for 
each group (Sh B6D2F1, Nx B6D2F1, Sh FVB/N and Nx FVB/N) and each time point (30, 
42 and 60 days after Nx). For microarray experiments, FVB/N and C57BL/6 mice were 
subjected to either sham operation or Nx (n = 4 for each group and genetic background) and 
sacrificed 60 days after surgery. For Stat3 deletion experiments, we generated double 
transgenic FVB/N Stat3flox/flox X Ksp.creERT2 mice (Stat3Δtub mice) that we compared to FVB/N 
Stat3flox/flox mice (Stat3flox mice). All mice were treated with tamoxifen at the dose of 7 mg per 
40 g of body weight per day in ethanol:oil (10:1). Tamoxifen was delivered through 
intraperitoneal injection for five consecutive days. Two weeks after tamoxifen treatment, 
mice underwent either sham operation (n = 3 and 4 for Stat3flox and Stat3Δtub mice, 
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respectively) or Nx (n = 9 and 13 for Stat3flox and Stat3Δtub mice, respectively). Mice were 
sacrificed 90 days after surgery and the kidneys were harvested for analysis. This later time 
point was used because we noticed that tamoxifen treatment slowly delays renal lesion 
progression after Nx. For Rosa26 experiments, Rosa26 mice expressing (n = 4) or not (n = 2) 
the Ksp.creERT2 transgene were induced by tamoxifen and sacrificed 2 weeks after tamoxifen 
treatment. 
Renal morphology  
Kidneys were fixed in 4% paraformaldehyde, paraffin embedded, and 4-µm sections were 
stained with Periodic Acid Schiff (PAS), Masson’s trichrome, Hematoxylin Eosin (HE) and 
picro-sirius red. The degree of glomerular lesions and interstitial cellular infiltration was 
evaluated using a semiquantitative score methodology as previously described33, with minor 
modifications69. Briefly, ten randomly selected cortical microscopic fields were scored. 
Glomerular lesions were evaluated on PAS-stained sections and graded from 0 to 3, according 
to the extent of sclerosis 0, 1, 2, 3 and 4 corresponding to glomerulosclerosis affecting less 
than 10%, 10 to 24%, 25 to 50% or more than 50% respectively. The degree of interstitial 
mononuclear cell infiltration was determined on H&E-stained sections using a 0-3 injury 
score: 0, 1, 2 and 3 corresponding to 0%, 1–10%, 10–30% and >30% involvement of the 
microscopic field, respectively. The degree of tubular dilation and interstitial fibrosis was 
automatically quantified using a Nikon digital camera Dx/m/1200 and NIS software 
(Laboratory Imaging Ltd). Ten randomly selected microscopic fields (X200) were scored. 
Surgical scars were excluded from analysis.  
Expression microarray 
Total RNA was extracted and purified from remnant kidneys of FVB/N and C57BL/6 using 
the Qiagen RNeasy Mini Kit (Qiagen) as suggested by the manufacturer. RNA was then 
quantified and inspected with a Bioanalyzer (Agilent Technologies). cDNAs were generated 
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and hybridized on mouse 430.2 Affymetrix chips (45101 probes) according to the Affymetrix 
protocol. 
Genome wide in silico analysis of potential Stat3 binding sites 
The method used for the construction of Stat3 positional weight matrix and the identification 
of Stat3 binding sites have been previously described16. The comparative genomic analysis 
was conducted as previously described with slight modifications: eight genomes were used 
for comparative analysis (Mus musculus, Rattus norvegicus, Homo sapiens, Gallus gallus, 
Canis familiar, Danio rerio, Xenopus tropicalis, Tetraodon nigroviridis) and only the binding 
sites located up to 15 kb upstream of the Transcription Start Site (TSS) were considered for 
further analysis.  
Quantitative RT-PCR 
 mRNA was detected in mouse kidneys by quantitative RT-PCR using ABI PRISM 7700 
Sequence Detection system (Applied Biosystems). Rpl13 was used as the normalization 
controls. Primers (Eurogentec) are listed in Supplemental Table 2. 
Western blot 
Western blot were performed as previously described70. Primary antibodies used were: rabbit 
polyclonal anti-Stat3 (Cell Signaling Technology), rabbit monoclonal anti-p-Stat3 (Y706) (Cell 
Signaling Technology), mouse monoclonal anti-α-tubulin antibody (Sigma-Aldrich), goat 
anti-Lcn2 antibodies (R&D system) at 1:2000 and mouse monoclonal anti-β-tubulin antibody 
(Sigma-Aldrich). 
Immunohistochemistry, immunofluorescence and β-galacosidase staining 
For immunohistochemistry, 4-µm sections of paraffin-embedded kidneys were submitted to 
the appropriate antigen retrieval. Then, sections were incubated with rabbit monoclonal anti-
p-Stat3 (Y706) antibodies (Cell Signaling Technology) at 1:100, anti-Stat3 rabbit polyclonal 
antibodies (Cell Signaling Technology), mouse anti-α−smooth muscle actin antibodies 
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(Dako) at 1:10000, rabbit anti-S100a4 antibodies (Abcam) at 1:200, goat anti-Tamm-Horsfall 
antibodies (Biogenesis) at 1:200, rabbit anti-Aquaporin 2 antibodies (Sigma-Aldrich) 1:400, 
goat anti-Lcn2 antibodies (R&D systems) at 1:300, mouse anti-Timp-1 antibodies (Pierce) at 
1:100, rabbit anti-collagen IV alpha chain 1 (Novusbio) at 1:100, followed by the appropriate 
secondary antibody. For colocalization experiments with tubular markers, 4-mm serial 
sections of paraffin-embedded kidneys were used. Proximal tubules were stained using 
biotinylated-Lotus Tetragonolobus Lectin (Vector) at 1:50 followed by HRP-labeled 
streptavidin at 1:1000. β-galacosidase staining was performed as previously described71. All 
immunofluorescence co-localization studies were analyzed using an Axio-observer Z1 
microscope with an ApoTome2 module (Zeiss), with the exception of Col4α1 and lcn2 co-
staining, which was analyzed using a LSM 700 confocal microscope (Zeiss). 
Pdgfb in situ Hybridisation  
Murine Pdgfb chain cDNA cloned into pBluescript.SK (a kind gift from Cecilia Bondjers, 
Gottenberg University, Sweden) was linearized with XbaI (anti-sense probe) or HindIII (sense 
probe) and labelled RNA probes were synthesized with T7 RNA polymerase (anti-sense 
probe) or T3 RNA polymerase (sense probe) using dNTP mix containing digoxigenin-labelled 
uridine-triphosphate as substrate (Roche). In situ hybridization was carried out on 8 µm 
paraffin embedded sections. Sections were permeabilized in 0.2 N hydrochloric acid, digested 
with 10 µg/ml proteinase K (Roche), acetylated in 0.5% acetic anhydride and then hybridized 
overnight at 65 °C with 1 µg/ml of RNA probe. After washings, the slides were blocked in 
10% goat serum and digoxin was revealed with anti-digoxigenin antibodies (Roche) at 
1:1500, followed with nitroblue tetrazolium/bromochloroindolylphosphate (NBT/BCIP) AP 
substrate solution (Roche).  
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Cell culture  
Mouse inner medulla collecting duct (mIMCD-3) cells were grown in DMEM/HamF12 
(Gibco) medium containing 10% Fetal Bovine Serum (FBS, Sigma). To obtain optimal 
cellular differentiation and polarization, cells were plated at confluence on transwell 0.4-µm 
polycarbonate filters (Corning) and cultured for a minimum of 5 days. Prior to experiments, 
cells were starved in a serum free medium overnight. Then cells were exposed for 24h to 
Oncostatin (Osm, 20 ng/ml, R&D Systems), Lif (100 ng/ml, Life Technologies) or IL-6 (100 
ng/ml, Life Technologies). 
For stable cell lines, mIMCD-3 cells expressing shRNA against Stat3 or Lcn2 were generated 
as follows. Lentiviral shRNA plasmids for Stat3 were obtained from Sigma-Aldrich. We used 
a target set of five clones with pLKO.1-puro as a backbone (TRCN0000071453, 
TRCN0000071454, TRCN0000071456, TRCN0000301878, TRCN0000301880 for Stat3 and 
TRCN0000425227, TRCN0000432763, TRCN0000425363, TRCN0000431679, 
TRCN0000055328 for Lcn2). The lentiviral particles were produced by cotransfection of 
HEK293T cells with three plasmids (pMD2G, psPAX2 and the shRNA vector) using 
lipofectamine 2000 (Lifetechnologies). Cells were infected in the presence of 8 µg/ml 
polybrene overnight and were selected 2 days after viral transduction in puromycin (2 µg/ml). 
Lentiviral constructs were selected for the subsequent experiments according to Stat3 or Lcn2 
protein reduction as evaluated by western blot analysis. 
Data analysis and statistics 
Data were expressed as means ± SEM. Differences between the experimental groups were 
evaluated using ANOVA, followed when significant (P < 0.05) by the Tukey-Kramer test. 
When only two groups were compared, Student T-test or Mann-Whitney test were used as 
appropriate. For microarray experiments, results are expressed as a Log2 of the ratio 
Cy5/Cy3. Genes with a false-discovery rate (FDR) < 0.05 (using the Benjamini-Hochberg 
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procedure) and a fold change (FC) > 1.5 were considered significant. The statistical analysis 
was performed using Graphpad Prism Software. 
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FIGURE LEGENDS 
Figure 1: Stat3 activation after nephron reduction in kidneys from lesion-resistant and 
lesion-prone mice. (A) Upper panel: periodic acid schiff staining (PAS) of remnant kidneys 
from C57BL/6, B6D2F1 and FVB/N mice 60 days after 75% nephrectomy (Nx). Lower 
panel: representative p-Stat3  (Y706) immunostaining in the same animals. Scale bar: 100 µm 
(n=6 per group). (B) Western blot of Stat3 (Y706) phosphorylation of whole kidney lysates of 
sham-operated  (Sh) and 75% nephrectomised (Nx) B6D2F1 and FVB/N mice 30 (n=6 in 
each group), 42 (n=5 in each group) and 60 (n=6 in each group) days after surgery. Data are 
means ± SEM. ANOVA followed by Tukey-Kramer test. Sh versus Nx mice: * P < 0.05, ** P 
< 0.01, *** P < 0.001; B6D2F1 versus FVB/N mice: # P < 0.05, ## P < 0.01, ### P < 0.001. 
(C) Representative p-Stat3  (Y706) immunostaining of kidneys from the same animals. 
Because kidneys from Sh B6D2F1 and Sh FVB/N mice were indistinguishable, only a single 
Sh control is shown. These are representative image of at least 5 mice in each group. Scale 
bar: 100 µm. 
Figure 2: Localization of Stat3 activation during renal lesion development. Upper panel:  
representative co-immunostaining experiments and quantification of p-Stat3 (Y706) and 
specific tubular markers, Tamm-Horshfall [ascending loop of Henle and the distal convoluted 
tubule (blue arrow)], lotus tetragonolobus lectin [proximal tubules (black arrow)] and 
aquaporin 2 [collecting tubule (green arrow)] in FVB/N remnant kidneys 42 and 60 days after 
75% subtotal nephrectomy (n=3 in each group). Scale bar: 100 µm. Lower panel: 
quantification of the percentage of p-Stat3 positive tubules marked with each of the markers. 
Figure 3: Conditional inducible deletion of Stat3 in renal tubules of adult mice. (A) 
Detection of Stat3 wild type (wt), floxed (fl) and deleted (Δ) allele on genomic DNA from the 
indicated tissue of wild type, Stat3fl/+, Stat3fl/fl (Stat3flox) and Stat3fl/fl Ksp.creERT2 (Stat3Δtub) 
mice two weeks after tamoxifen treatment. (B-C) Analysis of renal Stat3 expression by 
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western-blot (B) and immunohistochemistry (C) in Stat3flox (n=3) and Stat3Δtub (n=4) mice two 
weeks after tamoxifen treatment. (D-E) Western blot analysis and quantification of Stat3 
(Y706) phosphorylation (D) and Socs3 mRNA expression (E) in sham-operated (Sh) Stat3flox 
(n=3), Sh Stat3Δtub (n=4), 75% nephrectomized (Nx) Stat3flox (n=9) and Nx Stat3Δtub (n=10) 
mice 90 days after surgery. Data are means ± SEM. t-test (in B) or ANOVA followed by 
Tukey-Kramer test (in D and E). Sh versus Nx mice: * P < 0.05, ** P < 0.01; Stat3flox versus 
Stat3Δtub mice: # P < 0.05, ## P < 0.01. Scale Bar: 50 µm. 
Figure 4: Tubular Stat3 inactivation reduces tubulo-interstitial lesions after nephron 
reduction. Morphology and lesion scores of kidneys from sham-operated (Sh) Stat3flox (n=3) 
and Stat3Δtub (n=4) mice and 75% nephrectomized (Nx) Stat3flox (n=9) and Stat3Δtub (n=13) mice 
90 days after surgery. Data are means ± SEM. ANOVA followed by Tukey-Kramer test. Sh 
versus Nx mice: * P < 0.05, ** P < 0.01; Stat3flox versus Stat3Δtub mice: # P < 0.05, ## P < 0.01. 
Scale Bar: 100 µm. 
Figure 5: Tubular Stat3 inactivation reduces interstitial collagen content and α-sma+ 
fibroblasts density after nephron reduction. (A) Quantitative RT-PCR of renal collagen 
mRNA content in kidneys from sham-operated (Sh) Stat3flox (n=3) and Stat3Δtub (n=4) mice 
and 75% nephrectomized (Nx) Stat3flox (n=9) and Stat3Δtub (n=13) mice 90 days after surgery. 
(B) Representative α-sma immunostaining and quantification of α-sma+ cell density in sham-
operated (Sh) Stat3flox (n=3) and Stat3Δtub (n=4) mice and 75% nephrectomized (Nx) Stat3flox 
(n=9) and Stat3Δtub (n=13) mice 90 days after surgery. (C) Representative S100a4 
immunostaining and quantification of S100a4+ cell density of the same animals. (D) 
Representative colocalization between Pdgfr-β and α-sma (upper) and p-Stat3 (Y706) and 
α-sma (lower) on serial sections of remnant kidneys of FVB/N mice 60 days after Nx. Data 
are means ± SEM. ANOVA followed by Tukey-Kramer test. Sh versus Nx mice: * P < 0.05, 
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** P < 0.01, *** P < 0.001; Stat3flox versus Stat3Δtub mice: # P < 0.05, ## P < 0.01, ### P < 
0.001. Scale Bars: 50 µm. 
Figure 6: Potential Stat3 target genes during renal lesion development. (A) Comparison 
of the frequency of predicted Stat3 binding sites in whole mouse genome (grey) and in the 
genes differentially expressed by C57BL/6 (n=4) and FVB/N (n=4) remnant kidneys 60 days 
after 75% nephrectomy (Nx). The green histogram shows all the differentially expressed 
genes (either up or down regulated in FVB/N mice as compared to C57BL/6 animals), while 
the red and the blue histograms concern only the genes up and down regulated in FVB/N as 
compared to C57BL/6 mice, respectively. (B) Schematic representation of the intersection 
between the genes with Stat3 binding sites conserved at least in 4 species and the genes 
differentially expressed between C57BL/6 and FVB/N remnant kidneys 60 days after Nx.  
Figure 7: Tubular Stat3 inactivation affects the expression of specific paracrine 
fibrogenic factors after nephron reduction. Quantitative RT-PCR of the 16 potential 
paracrine profibrotic Stat3 targets in sham-operated (Sh) Stat3flox (n=3) and Stat3Δtub (n=4) 
mice and 75% nephrectomized (Nx) Stat3flox (n=9) and Stat3Δtub (n=13) mice 90 days after 
surgery. All relative expression are normalized to Rpl13. Data are means ± SEM. ANOVA 
followed by Tukey-Kramer test. Sh versus Nx mice: * P < 0.05, ** P < 0.01, *** P < 0.001; 
Stat3flox versus Stat3Δtub mice: # P < 0.05, ## P < 0.01, ### P < 0.001. 
Figure 8: Stat3 regulates the expression of Lcn2, Timp1 and Pdgfb in renal tubular cells. 
(A) Co-localization between p-Stat3 (Y706) and Lcn2 in the remnant kidney of FVB/N mice 60 
days after 75% subtotal nephrectomy (Nx). Scale Bar: 50 µm (B) Immunostaining of p-Stat3 
(Y706) (upper panel) and Timp1 (lower panel) on serial kidney sections from FVB/N mice 60 
days after Nx. Scale Bar: 100 µm. (C) Immunostaining of p-Stat3  (Y706) (upper panel) and in 
situ hybridization of Pdgfb mRNA (lower panel) on kidney serial sections from FVB/N mice 
60 days after Nx. Scale Bar: 100 µm. (D-E) Western-blot of Stat3 (Y706) phosphorylation (D) 
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and quantitative RT-PCR of Socs3, Lcn2, Timp1 and Pdgfb mRNA (E) from mIMCD3 cells 
treated with oncostatin M (Osm), leukemia inhibiting factor (Lif), interleukin-6 (IL-6) or 
vehicle (Veh). (F) Western blot of Stat3 from mIMCD3 transduced with a short hairpin RNA 
targeting Stat3 (Stat3) or a scramble control (Scr). (G) Quantitative RT-PCR of Socs3, Lcn2, 
Timp1 and Pdgfb mRNA expression in mIMCD3 transducted with a short hairpin RNA 
targeting Stat3 or a scramble control and treated with Osm or Veh. All relative expression are 
normalized to Rpl13. Data are means ± SEM. ANOVA followed by Tukey-Kramer test: Veh 
versus Osm, Lif or IL-6 treated cells: * P < 0.05, ** P < 0.01, *** P < 0.001; Cells transduced 
with a Stat3 Sh RNA versus a scramble Sh RNA: # P < 0.05, ## P < 0.01, ### P < 0.001. 
Figure 9: Lcn2 promotes collagen expression in renal tubular cells. (A) Western blot 
analysis of Lcn2 expression in mIMCD3 cells transduced with either a short hairpin RNA 
targeting Lcn2 (Lcn2) or a scramble control (Scr). (B) Quantitative RT-PCR of Col1a1 and 
Col4a1 mRNA expression in mIMCD3 cells transduced with either a short hairpin RNA 
targeting Lcn2 (Lcn2) or a scramble control. Data are means ± SEM. Paired T-test: ** P < 
0.01. (C) Representative confocal images of kidney sections from sham-operated (Sh; n=4) or 
75% nephrectomized (Nx; n=6) FVB/N mice 60 days after surgery stained with Lcn2 and 
Col4a1 chain specific antibodies. Scale bar: 20 µm. 
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Table 1: Potential Stat3 paracrine targets involved tubulo-interstitial communication.  
 
 
 
 
 
 
 
 
Gene 
Symbol 
Name Fold variation 
FVB/N vs C57Bl/6  
Stat3 binding sites 
conservation 
Lcn2 lipocalin 2 6.52 4 species 
Edn1 endothelin 1 4.07 4 species 
Cyr61 cysteine-rich, angiogenic inducer, 61 3.94 4 species 
Fst follistatin 3.70 6 species 
Timp1 tissue inhibitor of metalloproteinase 1 3.27 4 species 
Tgm1 transglutaminase 1 2.80 4 species 
Tgfb2 transforming growth factor, beta 2 2.43 4 species 
Ctgf connective tissue growth factor 2.21 4 species 
Adm adrenomedullin 2.11 4 species 
Plau plasminogen activator, urokinase 2,04 4 species 
Tagln2 transgelin 2 1.71 4 species 
Agt angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8) 
1.63 5 species 
Pdgfb platelet-derived growth factor beta 
polypeptide 
1.53 4 species 
Angpt1 angiopoietin 1 0.64 5 species 
Enpp2 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
(autotaxin) 
0.51 4 species 
Sfrp1 secreted frizzled-related protein 1 0.30 4 species 
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